- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04792073
Study of Avelumab and/or Radiation Therapy in People With Advanced Merkel Cell Carcinoma
A Phase II Single-Arm Clinical Trial Assessing Comprehensive Ablative Radiation Therapy With Avelumab in Unresectable and Metastatic Merkel Cell Carcinoma (CARTA)
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Christoper Barker, MD
- Phone Number: 212-639-8168
- Email: barkerc@mskcc.org
Study Contact Backup
- Name: Sandra D'Angelo, MD
- Phone Number: 646-888-4159
Study Locations
-
-
New Jersey
-
Basking Ridge, New Jersey, United States, 07920
- Recruiting
- Memorial Sloan Kettering Basking Ridge (All Protocol Activities)
-
Contact:
- Christopher Barker, MD
- Phone Number: 212-639-8168
-
Middletown, New Jersey, United States, 07748
- Recruiting
- Memorial Sloan Kettering Monmouth (All Protocol Activities)
-
Contact:
- Christopher Barker, MD
- Phone Number: 212-639-8168
-
Montvale, New Jersey, United States, 07645
- Recruiting
- Memorial Sloan Kettering Bergen (All Protocol Activities)
-
Contact:
- Christopher Barker, MD
- Phone Number: 212-639-8168
-
-
New York
-
Commack, New York, United States, 11725
- Recruiting
- Memorial Sloan Kettering Commack (All protocol activities)
-
Contact:
- Christopher Barker, MD
- Phone Number: 212-639-8168
-
Harrison, New York, United States, 10604
- Recruiting
- Memorial Sloan Kettering Westchester (All Protocol Activities)
-
Contact:
- Christopher Barker, MD
- Phone Number: 212-639-8168
-
New York, New York, United States, 10065
- Recruiting
- Memorial Sloan Kettering Cancer Center (All Protocol Activities)
-
Contact:
- MD
-
Contact:
- Christopher Barker, MD
- Phone Number: 212-639-8168
-
Uniondale, New York, United States, 11553
- Recruiting
- Memorial Sloan Kettering Nassau (All Protocol Activities)
-
Contact:
- Christopher Barker, MD
- Phone Number: 212-639-8168
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Biopsy proven Merkel cell carcinoma which is unresectable or metastatic, stage III or IV
Prior first-line treatment with aPD1 monotherapy (defined as at least one dose of pembrolizumab, avelumab, nivolumab, etc.) with evidence of progression of disease ≥10 weeks after starting therapy, in the absence of significant clinical deterioration
- Patients with clinical deterioration during aPD1 monotherapy are eligible ≥6 weeks after starting aPD1 therapy
- Criteria for clinical deterioration to be determined and agreed upon by treating physician and Principal Investigator
- All detectable sites of MCC are amenable to comprehensive ablative radiation therapy in opinion of treating radiation oncologist and principal investigator
- ≥18 years of age
- Performance status ≤2 on the Eastern Cooperative Oncology Group Performance Scale
- Able to provide valid written informed consent
Normal organ and marrow function
- Hematologic: Lymphocyte count ≥800/mm^3, neutrophil count ≥1500/mm^3, platelet count ≥75,000/mm^3, leukocyte count ≥3000/mm^3, hemoglobin ≥9 g/dL
- Hepatic: Total bilirubin ≤ 1.5 times the upper limit of normal, unless Gilbert's syndrome; aspartate transaminase and alanine transaminase ≤ 2.5 times the upper limit of normal (in the absence of hepatobiliary metastases); ≤ 3.0 times the upper limit of normal (in the presence of hepatobiliary metastases)
- Renal: Estimated creatinine clearance ≥ 30 mL/min according to the Cockcroft-Gault formula.
Exclusion Criteria:
- Prior systemic therapy for MCC other than first-line aPD1 monotherapy (ie, chemotherapy)
- Pregnancy or breastfeeding
Adverse events due to prior cancer therapy which are grade 3 or higher and have not resolved
°Patients with prior grade 3 or higher immune related adverse events are not eligible, even if they have resolved
- Prior severe hypersensitivity reaction (CTCAE version 5.0 grade ≥3) to avelumab
Prior radiotherapy which precludes the ability to safely deliver comprehensive ablative radiation therapy in the opinion of the treating radiation oncologist and principal investigator
°Institutional guidelines for reirradiation will be used when making this determination
- Known central nervous system metastases
Known clinically significant cardiovascular disease, defined as:
- Stroke or myocardial infarction within 6 months of first dose of avelumab
- Symptomatic congestive heart failure (New York Heart Association Class 2 or higher)
- Serious arrhythmia requiring anti-arrhythmic agents
- Known Human Immunodeficiency Virus infection
- Known Hepatitis B or C infection requiring ongoing treatment
Vaccination within 4 weeks of first dose of avelumab
°Inactivated vaccines are permissible
- Iatrogenic immunosuppression with daily systemic corticosteroid equivalent of >10 mg of prednisone
Active autoimmune disease that may cause clinical deterioration during immunotherapy
°Including, but not limited to:
- Inflammatory bowel disease or immune colitis
- Immune mediated pneumonitis or pulmonary fibrosis
- History of solid organ or hematopoietic transplant
- Active infection requiring systemic therapy
- Active suicidal ideation or behavior
- Comorbid or diagnostic abnormalities which would interfere with interpretation of study results
- Known hematopoietic cancer or dysfunction (i.e., leukemia, lymphoma)
- Known non-MCC solid tumor with known metastasis or estimated risk of metastasis >20% within 3 months
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Avelumab and Radiation Therapy
Will receive avelumab at the FDA approved dose and schedule of 800 mg IV over 60 minutes every 2 weeks (+/- 3 days) until treatment intolerance or disease progression occurs or 2 years of study therapy have been administered; standard of care Avelumab therapy after 2 years is permitted.
Comprehensive Ablative Radiation Therapy (CART) will be initiated between the first and second dose of Avelumab.
Comprehensive ablative radiation therapy will be given according to guidelines.
|
Avelumab 800 mg given intravenously over 60 minutes every 2 weeks (+/- 3 days)
Comprehensive ablative radiation therapy 24 Gy in 3 fractions every 2-3 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
progression free survival
Time Frame: at 12 weeks
|
measured by RECIST 1.1
|
at 12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
overall response rate
Time Frame: up to 12 weeks
|
measured by RECIST 1.1
|
up to 12 weeks
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Christoper Barker, MD, Memorial Sloan Kettering Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Virus Diseases
- Infections
- Neoplasms by Histologic Type
- Neoplasms
- Adenocarcinoma
- Neoplasms, Glandular and Epithelial
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- DNA Virus Infections
- Tumor Virus Infections
- Neuroendocrine Tumors
- Polyomavirus Infections
- Carcinoma, Neuroendocrine
- Carcinoma
- Carcinoma, Merkel Cell
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Avelumab
Other Study ID Numbers
- 20-195
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Merkel Cell Carcinoma
-
National Cancer Institute (NCI)Active, not recruitingAdvanced Merkel Cell Carcinoma | Metastatic Merkel Cell Carcinoma | Pathologic Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 | Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 | Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8 | Pathologic Stage IIIA Cutaneous Merkel... and other conditionsUnited States
-
National Cancer Institute (NCI)RecruitingMetastatic Merkel Cell Carcinoma | Refractory Merkel Cell Carcinoma | Locally Advanced Merkel Cell Carcinoma | Unresectable Merkel Cell Carcinoma | Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 | Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8United States
-
National Cancer Institute (NCI)CompletedRecurrent Merkel Cell Carcinoma | Stage III Merkel Cell Carcinoma AJCC v7 | Stage IV Merkel Cell Carcinoma AJCC v7 | Stage IIIA Merkel Cell Carcinoma AJCC v7 | Stage IIIB Merkel Cell Carcinoma AJCC v7United States
-
Melanoma and Skin Cancer Trials LimitedRecruitingNeuroendocrine Tumors | Merkel Cell Carcinoma | Merkel Cell Carcinoma, Stage I | Merkel Cell Carcinoma, Stage II | Merkel Cell Carcinoma, Stage III | Carcinoma Neuroendocrine SkinAustralia, New Zealand
-
University of WashingtonEMD SeronoActive, not recruitingStage III Merkel Cell Carcinoma AJCC v8 | Stage IIIB Merkel Cell Carcinoma AJCC v8 | Stage IIIA Merkel Cell Carcinoma AJCC v8United States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)TerminatedRecurrent Merkel Cell Carcinoma | Stage IV Merkel Cell CarcinomaUnited States
-
National Cancer Institute (NCI)SuspendedPathologic Stage I Cutaneous Merkel Cell Carcinoma AJCC v8 | Pathologic Stage II Cutaneous Merkel Cell Carcinoma AJCC v8 | Pathologic Stage III Cutaneous Merkel Cell Carcinoma AJCC v8United States
-
ImmunityBio, Inc.UnknownStage IIIB Merkel Cell Carcinoma | Stage IV Merkel Cell CarcinomaUnited States
-
University of WashingtonIncyte CorporationRecruitingMerkel Cell Carcinoma | Clinical Stage IV Merkel Cell Carcinoma AJCC v8 | Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8United States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI); EMD SeronoTerminatedStage IV Merkel Cell Carcinoma AJCC v7 | Merkel Cell Polyomavirus InfectionUnited States
Clinical Trials on Avelumab
-
Merck KGaA, Darmstadt, GermanyCompleted
-
Clinique Neuro-OutaouaisCompletedGlioblastoma Multiforme of BrainCanada
-
Promontory Therapeutics Inc.Pfizer; EMD SeronoCompletedNon-Small Cell Lung Cancer (NSCLC)United States, Switzerland
-
Vaccinex Inc.University of RochesterRecruitingMetastatic Pancreatic AdenocarcinomaUnited States
-
Samsung Medical CenterMerck KGaA, Darmstadt, GermanyActive, not recruitingLymphoma, Extranodal NK-T-CellKorea, Republic of
-
4SC AGMerck KGaA, Darmstadt, GermanyWithdrawn
-
Merck KGaA, Darmstadt, GermanyCompletedSolid TumorsGermany
-
AHS Cancer Control AlbertaEMD Serono; Alberta Cancer FoundationRecruitingSquamous Cell Carcinoma of the SkinCanada
-
McGill University Health Centre/Research Institute...RecruitingGastric Adenocarcinoma | Esophageal AdenocarcinomaCanada
-
PfizerNot yet recruitingUrinary Bladder Neoplasms | Bladder Cancer | Urothelial Carcinoma | Bladder TumorsCanada